Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Potentials of Epigenetic Molecules in Attenuating the Phenotypes of Periodontitis

Award Number: R01DE032006
ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 06/15/2023
PERIOD OF PERFORMANCE END DATE: 04/30/2029

Group Awards By:

View Award Description

Potentials of Epigenetic Molecules in Attenuating the Phenotypes of Periodontitis - Periodontal disease represents one of the most prevalent diseases in adult population as 47% of Americans over age 30 have the disease. Periodontitis is a complex immune and inflammatory disease, characterized by three major pathological features: exacerbating inflammatory response, excess osteoclastic alveolar bone resorption and decreased osteoblastic bone formation. Unfortunately, there are only palliative treatments in clinics currently. Our laboratory has explored a variety of strategies to ameliorate the severity of the disease including application of bone marrow stromal cells (BMSCs) and induced pluripotent stem cells (iPSCs) with major transcription factors, such as Runx2, Osx and SATB2 in cell-based gene-therapy, but at the meantime experienced drawbacks and limitations of these approaches. Therefore, we are actively searching for a new therapy that blocks the major pathogenetic elements and stimulates endogenous factors to regenerate the tissues lost in periodontitis. Epigenetic molecules have recently emerged as potent regulators of gene expression and therapeutic agents for a variety of human diseases. We for the first time found that the novel synthetic BET protein inhibitor, JQ1, specifically inhibits periodontal inflammation and significantly reduces alveolar bone loss in murine periodontitis model. Additionally, we are the first to identify miR-335-5p and characterized its role in promoting bone formation and regeneration. Overexpressing miR-335-5p ameliorates tissue damage in experimental periodontitis which further provides a foundation and a strong premise for the current proposal. In this proposal we will use an elegantly designed and precisely synthesized nanoparticle (NP) system that will carry both JQ1 and miR-335-5p and specifically release them into major target cells in periodontitis, resulting in a block of the pathogenesis and activation of endogenous regenerative factors. In Aim 1, we will delineate the molecular mechanisms of miR-335-5p effects in periodontitis under gene deficient and overexpressing conditions using our newly generated genetically manipulated rodents. In Aim 2, we will define the epigenetic effects of nanoparticle-mediated precision and specific delivery of JQ1 and miR-335-5p on their corresponding target cells. In Aim 3, we will determine the therapeutic efficacy of combined application of epi-modulators in a mouse model of periodontitis. We will deliver the epi- biological nano-products simultaneously, individually, or alternatingly to assess the therapeutic impact at different disease stages. Outcome measures will include unbiased single cell RNA-sequencing, 16S rDNA profiling, qualitative and quantitative periodontal analyses and pharmacokinetics. Using innovative epigenetic approaches to understand the pathophysiology of periodontal disease and its therapeutic potentials is a paradigm shift. This investigation will be conducted by an interdisciplinary team composed of the PI and three C-Is who have profound knowledge and complementary skills in the following areas: Experimental Pathology and Bone Biology; Cell and Molecular Biology; Inflammation and Immunology, and Biomaterials and Drug Delivery.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $659,847 )
2026	2026	TRUSTEES OF TUFTS COLLEGE	136 HARRISON AVE	BOSTON	MA	02111	SUFFOLK	USA	Oral Diseases and Disorders Research	000	3	5/5/2026	NON-COMPETING CONTINUATION	$659,847
														Subtotal = $659,847

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	TRUSTEES OF TUFTS COLLEGE	136 HARRISON AVE	BOSTON	MA	02111	SUFFOLK	USA	Oral Diseases and Disorders Research	000	2	5/23/2025	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $646,651 )
2024	2024	TRUSTEES OF TUFTS COLLEGE	136 HARRISON AVE	BOSTON	MA	02111	SUFFOLK	USA	Oral Diseases and Disorders Research	000	2	5/7/2024	NON-COMPETING CONTINUATION	$593,863
2024	2024	TRUSTEES OF TUFTS COLLEGE	136 HARRISON AVE	BOSTON	MA	02111	SUFFOLK	USA	Oral Diseases and Disorders Research	001	2	6/19/2024	NON-COMPETING CONTINUATION	$52,788
														Subtotal = $646,651

Issue Date FY: 2023 ( Subtotal = $692,347 )
2023	2023	TRUSTEES OF TUFTS COLLEGE	136 HARRISON AVE	BOSTON	MA	02111	SUFFOLK	USA	Oral Diseases and Disorders Research	000	1	6/15/2023	NEW	$692,347
														Subtotal = $692,347

Grand Total All Awards = $1,998,845

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Potentials of Epigenetic Molecules in Attenuating the Phenotypes of Periodontitis

Award Number: R01DE032006

ORGANIZATION: NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 06/15/2023

PERIOD OF PERFORMANCE END DATE: 04/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer